
- RIUMA Principal
- Listar por autor
Listar por autor "Ciano-Petersen, Nicolas Lundahl"
Mostrando ítems 1-4 de 4
-
Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
Aguilar-Castillo, María José; Cabezudo-García, Pablo; Ciano-Petersen, Nicolas Lundahl; García-Martín, Guillermina; Marín-Gracia, Marta; Estivill-Torrús, Guillermo; Serrano-Castro, Pedro Jesús[et al.] (IOAP-MPDI, 2022-03-19)
Immunologic and neuroinflammatory pathways have been found to play a major role in the pathogenesis of many neurological disorders such as epilepsy, proposing the use of novel therapeutic strategies. In the era of personalized ... -
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis.
Ciano-Petersen, Nicolas Lundahl; Mélisse, Robert; Muñiz-Castrillo, Sergio; Wucher, Valentin; Klich, Amna; Alberto Vogrig, Alberto; Villagrán García, Macarena; Antonio Farina, Antonio; David Goncalves, David; Geraldine Picard, Geraldine; Veronique Rogemond, Veronique; Bastien Joubert, Bastien; Oliver-Martos, Begoña; Serrano-Castro, Pedro Jesús
; Maucort-Boulch, Delphine; Honnorat, Jerome[et al.] (American Academy of Neurology, 2023-05-05)
Background and objectives: Anti-NMDA receptor (NMDAR) encephalitis is defined by the presence of antibodies (Abs) targeting the NMDAR in the CSF. This study aimed to determine the prognostic value of persistent CSF NMDAR-Abs ... -
Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy
Aliaga-Gaspar, Pablo; Brichette-Mieg, Isabel; Fernández-Arjona, María del Mar; Rodríguez-Bada, José Luis; Lopez-Moreno, Yolanda; Serrano-Castro, Pedro Jesús; Fernández Fernández, Oscar; Ciano-Petersen, Nicolas Lundahl; Oliver-Martos, Begoña
[et al.] (Elsevier, 2024)
The soluble type I IFN receptor (sIFNAR2) is produced by alternative splicing and is present in body fluids. Although it can modulate IFN-ß activity, its biological role remains unknown. Methods: An in-silico study was ... -
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
Aliaga-Gaspar, Pablo; Hurtado-Guerrero, Isaac; Ciano-Petersen, Nicolas Lundahl; Urbaneja, Patricia; Brichette Mieg, Isabel; Virginia Reyes, Virginia; Rodríguez-Bada, José Luis; Alvarez-Lafuente, Roberto; Arroyo, Rafael; Quintana, Ester; Ramió-Torrentà, Lluis; Alonso, Ana; Leyva-Fernández, Laura; Fernández-Fernández, Óscar; Oliver-Martos, Begoña[et al.] (2021-12)
Protein and mRNA levels of sIFNAR2 increased after IFN-b treatment. According to the clinical response, only non-responders increased sIFNAR2 significantly at both protein and mRNA levels. sIFNAR2 gene expression correlated ...